<DOC>
	<DOC>NCT01195324</DOC>
	<brief_summary>The purpose of the study is to assess the effect of multiple oral doses of canagliflozin on a single oral dose of warfarin.</brief_summary>
	<brief_title>A Drug Interaction Study of Warfarin and Canagliflozin in Healthy Adult Volunteers</brief_title>
	<detailed_description>This is an open-label (volunteers will know the names of treatments they are assigned) single-center study of canagliflozin (JNJ-28431754) and warfarin in healthy adult volunteers. Canagliflozin is a drug currently under development to lower blood sugar levels in patients with type 2 diabetes mellitus and warfarin is an approved anticoagulant (ie, a drug that stops blood from clotting). After an overnight fast (without eating food) of at least 10 hours, volunteers will receive Sequence 1 (canagliflozin 300 mg, orally, once daily on Days 1-12 with a single, oral 30 mg dose of warfarin on Day 6 [Treatment A] followed 14 days later by a single, oral 30 mg dose of warfarin on Day 1 [Treatment B]) OR Sequence 2 (Treatment B followed 14 days later by Treatment A).</detailed_description>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Healthy volunteers with a body mass index between 18 and 30 kg/m Any blood coagulation disorder determined to be clinically relevant by the Investigator Medications known to affect coagulation taken within 7 to 14 days of study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Canagliflozin (JNJ-28431754)</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Pharmacodynamic</keyword>
	<keyword>Prothrombin time (PT)</keyword>
	<keyword>International normalized ratio (INR)</keyword>
</DOC>